Bioequivalence of a single 10-mg dose of finasteride 5-mg oral disintegrating tablets and standard tablets in healthy adult male Han Chinese volunteers: A randomized sequence, open-label, two-way crossover study

Clinical Therapeutics

Volumn 31, Issue 10, 2009, Pages 2242-2248

  Chen, Li ^a,b   Jiang, Xuehua ^a   Huang, Liang ^b   Lan, Ke ^a   Wang, Haiying ^b   Hu, Lina ^b   Ren, Jing ^a   Li, Xihong ^b   Zou, Qin ^b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

bioavailability; bioequivalence; finasteride; human; pharmacokinetics

Indexed keywords

FINASTERIDE;

ABSENCE OF SIDE EFFECTS; ADULT; AGE DISTRIBUTION; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD PRESSURE; BODY HEIGHT; BODY TEMPERATURE; BODY WEIGHT; BREATHING RATE; CHINA; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG TOLERABILITY; FOLLOW UP; HEART RATE; HEMATOLOGY; HUMAN; HUMAN EXPERIMENT; LABORATORY TEST; LIVER FUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TABLET DISINTEGRATION; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; URINALYSIS; VITAL SIGN; VOLUNTEER;

AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; ENZYME INHIBITORS; FINASTERIDE; HALF-LIFE; HUMANS; MALE; MASS SPECTROMETRY; SOLUBILITY; TABLETS; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 71549157424     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.09.015     Document Type: Article

References (20)

1. McConnell J.D., Bruskewitz R., Walsh P., et al., Finasteride Long-Term Efficacy and Safety Study Group. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 338 (1998) 557-563
2. Kaufman K.D., Olsen E.A., Whiting D., et al., Finasteride Male Pattern Hair Loss Study Group. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol. 39 (1998) 578-589
3. Almeida A., Almeida S., Filipe A., et al. Bioequivalence study of two different coated tablet formulations of finasteride in healthy volunteers. Arzneimittelforschung 55 (2005) 218-222
4. de Menezes F.G., Ribeiro W., Ifa D.R., et al. Bioequivalence study of finasteride. Determination in human plasma by high-pressure liquid chromatography coupled to tandem mass spectrometry. Arzneimittelforschung 51 (2001) 145-150
5. Steiner J.F. Clinical pharmacokinetics and pharmacodynamics of finasteride. Clin Pharmacokinet 30 (1996) 16-27
6. Carlin J.R., Höglund P., Eriksson L.O., et al. Disposition and pharmacokinetics of [14C]finasteride after oral administration in humans. Drug Metab Dispos. 20 (1992) 148-155
7. Girman C.J. Population-based studies of the epidemiology of benign prostatic hyperplasia. Br J Urol. 82 Suppl 1 (1998) 34-43
8. Proscar (finasteride) [prescribing information]. http://www.propecia.com/finasteride/propecia/consumer/product-information/pi/ Accessed September 22, 2009
9. Goel H., Rai P., Rana V., and Tiwary A.K. Orally disintegrating systems: Innovations in formulation and technology. Recent Pat Drug Deliv Formul 2 (2008) 258-274
10. State Food and Drug Administration Web site [in Chinese]. http://www.sda.gov.cn/WS01/CL0055/10368.html Accessed September 11, 2009
11. IV sets/syringes & needles. http://www.watkinssurgical.com/images/06_IVSyringes.pdf Accessed September 11, 2009
12. Lan K., Jiang X., Ren J., et al. Determination of finasteride in human plasma by HPLC-MS. Asian J Pharmacodynam Pharmacokinet 6 (2006) 196-202
13. US Food and Drug Administration, Center for Veterinary Medicine. Guidance for Industry. Bioequivalence guidance. http://www.fda.gov/downloads/AnimalVeterinary/Guidance-ComplianceEnforcement/GuidanceforIndustry/ucm052363.pdf Accessed September 18, 2009
14. US Food and Drug Administration. In vivo bioequivalence guidances. Pharmacopeial Forum 19 (1993) 6501-6508
15. Schuirmann D.J. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 15 (1987) 657-680
16. Propecia (finasteride) 1 mg [package insert]. http://www.merck.com/product/usa/pi_circulars/p/propecia/propecia_pi.pdf Accessed September 18, 2009
17. Huskey S.W., Dean D.C., Miller R.R., et al. Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride [published correction appears in Drug Metab Dispos. 1996;24695]. Drug Metab Dispos. 23 (1995) 1126-1135
18. Yasumori T., Narita H., Matsuda T., et al. Finasteride 1 mg has no inhibitory effect on omeprazole metabolism in extensive and poor metabolizers for CYP2C19 in Japanese. Eur J Clin Pharmacol. 62 (2006) 939-946
19. Wedlund P.J. The CYP2C19 enzyme polymorphism. Pharmacology 61 (2000) 174-183
20. Xiao Z.S., Goldstein J.A., Xie H.G., et al. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther. 281 (1997) 604-609